Tamura J, Kamano T, Azuma N, Katami A, Sato T, Uchida N, Kanno T, Sato T, Kiyatake I, Kakuhara T
Gan To Kagaku Ryoho. 1987 Sep;14(9):2771-4.
A patient under artificial dialysis due to chronic renal failure suffered from gastric cancer concurrently. This patient underwent subtotal gastrectomy followed by consecutive oral administration of 5-FU (tablets) as a postoperative adjuvant chemotherapy. The 5-FU level in the peripheral blood on oral administration at 50 mg remained at 0.007-0.01 microgram/ml over 2 hours. This feature of 5-FU blood level is not seen in gastric cancer patients with normal renal functions on administration of 5-FU tablets, and it seems to approximate the features of a 5-FU prodrug level in the blood upon oral administration. Neither the influence of dialysis on the absorption of orally administered 5-FU nor side effects caused by 5-FU were observed. The above findings suggest that it may be possible to maintain a certain blood level of 5-FU and to perform adjuvant chemotherapy even in cancer patients under artificial dialysis, as long as the dose is controlled carefully.
一名因慢性肾衰竭接受人工透析的患者同时患有胃癌。该患者接受了胃大部切除术，术后连续口服5-氟尿嘧啶（片剂）作为辅助化疗。口服50mg时，外周血中5-氟尿嘧啶水平在2小时内维持在0.007-0.01微克/毫升。在口服5-氟尿嘧啶片剂时，肾功能正常的胃癌患者未出现5-氟尿嘧啶血药水平的这种特征，这似乎类似于口服5-氟尿嘧啶前体药物时的血药特征。未观察到透析对口服5-氟尿嘧啶吸收的影响，也未观察到5-氟尿嘧啶引起的副作用。上述发现表明，只要仔细控制剂量，即使是接受人工透析的癌症患者，也有可能维持一定的5-氟尿嘧啶血药水平并进行辅助化疗。
